Phase III trial of Skyrizi meets all endpoints in plaque psoriasis.- AbbVie

Of patients treated with Skyrizi, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks (p<0.001). at week 16 skyrizi also met the other primary endpoint of non-inferiority to cosentyx with 74 percent of skyrizi patients achieving pasi 90 compared to 66 percent of cosentyx patients. skyrizi also showed superiority compared to cosentyx for all ranked secondary endpoints including pasi 100 and pasi 75 as well as a static physician global assessment score of clear or almost clear spga 0 1 at week 52 p><0.001).>

Current safety data available demonstrated that the safety profile of Skyrizi was consistent with that observed in previously reported studies, with no new safety signals observed through week 52. The rates of adverse events (AEs) were comparable between Skyrizi and Cosentyx. The most common AEs were nasopharyngitis, upper respiratory tract infection, headache, arthralgia and diarrhea. The rate of serious AEs were 5.5 percent in the Skyrizi group and 3.7 percent in the Cosentyx group. Adverse events leading to discontinuation of the study drug were 1.2 percent in the Skyrizi group and 4.9 percent in the Cosentyx group. There were no deaths in either treatment group.